How The World's Largest Cannabis Beverage Manufacturer Has Quietly Raised Over $250,000 From Retail Investors To Take On The Caffeine, CBD and THC Markets

Emerging biotech powerhouse Rexis Biotech is making significant strides in the consumer-packaged goods industry, with an innovative solution that boosts the efficiency and taste of plant-based ingredients in everyday products. The company recently launched on Wefunder, which means anyone can invest in Rexis Biotech for a limited time.

Click here to invest in Rexis Biotech.

The company’s proprietary technology aims to address two challenges plaguing the industry. First, the low bioavailability of plant-based ingredients such as caffeine, lion's mane, CBD, and THC, which leads to less absorption of these substances by the human body. Second, the bitter or oily aftertaste often associated with such ingredients.

Rexis Biotech’s solution helps these ingredients enter the bloodstream faster, providing a more robust effect while also improving taste. Essentially, Rexis Biotech has developed the "secret sauce" that makes consumer products across various industries stand out, enhancing the potential for brands to become award winners.

While known for their work in the consumer goods sector, Rexis Biotech’s capabilities extend into the pharmaceutical industry. The company is particularly optimistic about the approval and launch of several groundbreaking pharmaceutical therapies slated for release in 2023.

One notable pharmaceutical product is NX1 (pTeronsene), which shows promising results for tobacco smokers. In a double-blind, placebo-controlled study, over 95% of subjects reported a reduced or completely eliminated need to smoke. Such results present a potential breakthrough for those battling nicotine addiction.

To stay updated with top startup news & investments, sign up for Benzinga’s Startup Investing & Equity Crowdfunding Newsletter.

Another significant project is the development of a CBD-based epilepsy therapeutic, dubbed CX1-N1, which seeks to disrupt the market currently dominated by the FDA-approved Epidiolex. Preliminary trials showed CX1-N1 to be 523% more effective than Epidiolex.

Apart from these developments, the company is set to launch new retail-facing brands to expand its revenue streams. It is also projecting revenues of $14.7 million for 2023 and has secured multi-year revenue-generating contracts with seven top brands.

Rexis Biotech, which currently holds the position of the world’s largest cannabis beverage manufacturer, is operational in three countries and has ownership stakes in several hemp and THC manufacturing corporations.

Over the past year, Rexis Biotech has seen an impressive 78% increase in its share price, marking a period of explosive growth. With its transformative biotech solutions, the company is uniquely poised to reshape the landscape of both the consumer-packaged goods and pharmaceutical industries. As Rexis Biotech, Inc. continues to innovate, its contribution to these sectors is certainly one to watch closely.

See more on startup investing from Benzinga:

• Airbnb was worth $47 billion at IPO. This New ‘Airbnb For RV's' Platform Takes On $540 Million RV Rental Market With 25% In Savings And $50,000 For Renters. is open for anyone to invest.
• Don’t just buy from your favorite brands, own them so you own the upside. Learn how Retail Investors Are Taking Stakes In Their Favorite Startups To Own The Upside

Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer's securities at a rate of $5 CPC. This content is for informational purposes only and is not intended to be investing advice. Please see 17b disclosure linked in the campaign page for more information.